Furthermore, the development of a synthetic small-molecule p53 activator named NA-17, whose action would be mediated by reorganization of the Bak-Bcl-Xl complex and activation of transcriptional regulation, has shown hopeful results in preclinical models of NSCLC [157]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.